1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exagen Inc.
  6. News
  7. Summary
    XGN   US30068X1037

EXAGEN INC.

(XGN)
  Report
Delayed Nasdaq  -  05/25 04:00:00 pm EDT
4.630 USD   +0.22%
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus
GL
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus
AQ
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop Novel Patented Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection

01/09/2022 | 12:00pm EDT

Exagen Inc. and Queen Mary University of London, announced the execution of a research collaboration and exclusive license agreement. The collaboration will focus on development and optimization of patent-pending precision medicine approaches, based on RNA expression signatures, to personalize therapeutic agent selection for rheumatoid arthritis (RA) patients. Both parties will contribute to the development of the patent-pending assays, leading to the commercialization of novel molecular assays that segment patients according to gene expression in their synovial tissue biopsies. Building on Prof. Costantino Pitzalis and Dr. Myles Lewis’s molecular pathology definition of disease evolution and treatment response, Exagen has acquired an exclusive global license to a family of patent-pending assays pertaining to RNA expression patterns used in the prediction of patient response to commonly prescribed csDMARD and biological therapeutics for RA. The assays utilize minimally invasive synovial tissue biopsies as input, which are then assessed for RNA expression data. These data are then run through proprietary algorithms that provides actionable insights on predicted csDMARD and biological therapeutic response for RA patients based on an individual patient’s RNA expression patterns.


© S&P Capital IQ 2022
Stocks mentioned in the article
ChangeLast1st jan.
EVOLUTION AB -5.03% 929 Delayed Quote.-23.95%
EXAGEN INC. 0.22% 4.63 Delayed Quote.-60.19%
All news about EXAGEN INC.
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Di..
GL
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Di..
AQ
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Di..
CI
05/13KeyBanc Lowers Exagen's Price Target to $17 From $20, Maintains Overweight Rating
MT
05/11EXAGEN INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/11Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/11TRANSCRIPT : Exagen Inc., Q1 2022 Earnings Call, May 11, 2022
CI
05/11Earnings Flash (XGN) EXAGEN Reports Q1 Revenue $10.4M, vs. Street Est of $10M
MT
05/11Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Te..
GL
05/11Exagen Inc. Reports First Quarter 2022 Results
GL
More news
Analyst Recommendations on EXAGEN INC.
More recommendations
Financials (USD)
Sales 2022 53,4 M - -
Net income 2022 -35,2 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,23x
Yield 2022 -
Capitalization 75,3 M 75,3 M -
Capi. / Sales 2022 1,41x
Capi. / Sales 2023 1,14x
Nbr of Employees 221
Free-Float 58,9%
Chart EXAGEN INC.
Duration : Period :
Exagen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXAGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 4,63 $
Average target price 16,40 $
Spread / Average Target 254%
EPS Revisions
Managers and Directors
Fortunato Ron Rocca President, Chief Executive Officer & Director
Kamal Adawi Chief Financial Officer & Secretary
Brian P. Birk Chairman
Debra Jeske Zack Chief Medical Officer
Anja Kammesheidt Chief Scientific Officer